• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射两性霉素治疗念珠菌性腹膜炎:腹腔液抗生素水平

Management of Candida peritonitis with intravenous amphotericin: Peritoneal fluid antibiotic levels.

作者信息

Levin R M, Jason C, Black S, Nickolai D, Potter D, Grossman M

出版信息

Clin Pediatr (Phila). 1982 Nov;21(11):693-5. doi: 10.1177/000992288202101110.

DOI:10.1177/000992288202101110
PMID:7127992
Abstract

The child presented in this report received intravenous amphotericin B 0.5 mg/kg every 36 hours, for dialysis-associated Candida peritonitis. Just prior to her third dose of amphotericin B, the peritoneal fluid concentration of this drug was 0.1 mcg/ml, and the simultaneous serum level was 0.2 mcg/ml. An hour following the third amphotericin B dose, the peritoneal fluid and serum concentrations were 0.2 and 0.4 mcg/ml respectively. The minimal inhibitory concentration (MIC) of amphotericin B for the C. albicans isolated from this patient was 0.05 mcg/ml, and the minimal lethal concentration (MLC) was 0.1 mcg/ml. Treatment included concurrent 5-fluorocytosine, and catheter removal. This is the first time that measurements of concentrations of amphotericin B in the peritoneal fluid have been reported in a child with peritonitis.

摘要

本报告中所述患儿因透析相关性念珠菌性腹膜炎接受静脉注射两性霉素B,剂量为每36小时0.5mg/kg。就在她第三次注射两性霉素B之前,该药物的腹膜液浓度为0.1mcg/ml,同时血清水平为0.2mcg/ml。第三次注射两性霉素B一小时后,腹膜液和血清浓度分别为0.2mcg/ml和0.4mcg/ml。从该患者分离出的白色念珠菌对两性霉素B的最低抑菌浓度(MIC)为0.05mcg/ml,最低致死浓度(MLC)为0.1mcg/ml。治疗包括同时使用5-氟胞嘧啶,并拔除导管。这是首次报道在一名患有腹膜炎的儿童中测量腹膜液中两性霉素B的浓度。

相似文献

1
Management of Candida peritonitis with intravenous amphotericin: Peritoneal fluid antibiotic levels.静脉注射两性霉素治疗念珠菌性腹膜炎:腹腔液抗生素水平
Clin Pediatr (Phila). 1982 Nov;21(11):693-5. doi: 10.1177/000992288202101110.
2
Peritoneal penetration of amphotericin B lipid complex and fluconazole in a pediatric patient with fungal peritonitis.两性霉素B脂质复合物和氟康唑在一名真菌性腹膜炎儿科患者中的腹膜穿透情况。
Adv Perit Dial. 1998;14:247-50.
3
Therapy of Candida peritonitis: penetration of amphotericin B into peritoneal fluid.念珠菌性腹膜炎的治疗:两性霉素B在腹膜液中的渗透情况。
Postgrad Med J. 1978 May;54(631):340-2. doi: 10.1136/pgmj.54.631.340.
4
Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis.重症念珠菌性腹膜炎患者静脉治疗期间两性霉素B和氟胞嘧啶的血清及腹腔内水平。
J Antimicrob Chemother. 2007 May;59(5):952-6. doi: 10.1093/jac/dkm074. Epub 2007 Mar 27.
5
Persistence of Candida despite seemingly adequate systemic and intraperitoneal amphotericin B treatment in a patient on CAPD.一名接受持续性非卧床腹膜透析(CAPD)治疗的患者,尽管接受了看似足够的全身性和腹腔内两性霉素B治疗,但念珠菌仍持续存在。
Am J Kidney Dis. 1986 Oct;8(4):265-6. doi: 10.1016/s0272-6386(86)80038-5.
6
Candida peritonitis complicating peritoneal dialysis: successful treatment with low dose amphotericin B therapy.
Clin Nephrol. 1976 Nov;6(5):492-6.
7
Candida peritonitis-inefficacy of amphotericin-B and 5-fluorocytosine treatment.念珠菌性腹膜炎——两性霉素B和5-氟胞嘧啶治疗无效
Int J Pediatr Nephrol. 1983 Jun;4(2):127-8.
8
Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in continuous ambulatory peritoneal dialysis.静脉注射两性霉素B与口服氟胞嘧啶联合治疗真菌性腹膜炎,并在持续性非卧床腹膜透析中延迟更换导管。
Perit Dial Int. 2008 Mar-Apr;28(2):155-62.
9
Antifungal treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis patients.持续性非卧床腹膜透析患者念珠菌性腹膜炎的抗真菌治疗
Am J Kidney Dis. 1987 Jan;9(1):66-70. doi: 10.1016/s0272-6386(87)80164-6.
10
Non Candida albicans fungal peritonitis in continuous ambulatory peritoneal dialysis patients.持续性非卧床腹膜透析患者的非白色念珠菌真菌性腹膜炎
Adv Perit Dial. 2001;17:176-9.

引用本文的文献

1
Tissue penetration of antifungal agents.抗真菌药物的组织穿透性。
Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13.